Registration Dossier
Registration Dossier
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 242-367-1 | CAS number: 18480-07-4
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data

Acute Toxicity: dermal
Administrative data
- Endpoint:
- acute toxicity: dermal
- Data waiving:
- study scientifically not necessary / other information available
- Justification for data waiving:
- the study does not need to be conducted because the substance is classified as corrosive to the skin
- the study does not need to be conducted because the physicochemical and toxicological properties suggest no potential for a significant rate of absorption through the skin
Cross-referenceopen allclose all
- Reason / purpose for cross-reference:
- data waiving: supporting information
Reference
- Name:
- Strontium hydroxide
- Implementation:
- EU
- Type of classification:
- self-classification
- Remarks:
- no 'extra' classification for hydrated form
- Related composition:
- Strontium hydroxide
- Reason for no classification:
- data lacking
- Reason for no classification:
- data lacking
- Reason for no classification:
- data lacking
- Reason for no classification:
- hazard class not assessed
- Reason for no classification:
- data lacking
- Reason for no classification:
- data lacking
- Reason for no classification:
- data lacking
- Reason for no classification:
- data lacking
- Reason for no classification:
- data lacking
- Reason for no classification:
- data lacking
- Reason for no classification:
- data lacking
- Reason for no classification:
- data lacking
- Reason for no classification:
- data lacking
- Reason for no classification:
- data lacking
- Reason for no classification:
- data lacking
- Reason for no classification:
- data lacking
- Reason for no classification:
- data lacking
- Reason for no classification:
- data lacking
- Reason for no classification:
- data lacking
- Reason for no classification:
- data lacking
- Reason for no classification:
- data lacking
- Hazard category:
- Skin Corr. 1A
- Hazard statement:
- H314: Causes severe skin burns and eye damage.
- Hazard category:
- Eye Damage 1
- Hazard statement:
- H318: Causes serious eye damage.
- Reason for no classification:
- data lacking
- Reason for no classification:
- data lacking
- Reason for no classification:
- data lacking
- Reason for no classification:
- data lacking
- Reason for no classification:
- data lacking
- Reason for no classification:
- data lacking
- Reason for no classification:
- data lacking
- Reason for no classification:
- data lacking
- Reason for no classification:
- data lacking
- Reason for no classification:
- data lacking
- Reason for no classification:
- data lacking
- Reason for no classification:
- data lacking
- Signal word:
- Danger
- Code:
- GHS05: corrosion
- Hazard statement:
- H314: Causes severe skin burns and eye damage.
- Additional non-GHS hazard statement:
- EUH071: Corrosive to the respiratory tract.
- Reason / purpose for cross-reference:
- data waiving: supporting information
Reference
- Absorption rate - oral (%):
- 20
- Absorption rate - dermal (%):
- 1
- Absorption rate - inhalation (%):
- 8.9
Oral absorption; ATSDR, August 2004; key conclusions
“The
fractional absorption of ingested strontium has been estimated in
healthy human subjects or hospital patients who received an oral dose of
strontium chloride (SrCl2) or ingested strontium in the diet
(ATSDR, 2004 Table 3-7). Absorption was quantified in these studies from
measurements of plasma strontium concentration-time profiles for
ingested and intravenously injected strontium (bioavailability), or from
measurements of the difference between the amount ingested and excreted
in feces (balance). Collectively, the results of these studies indicate
that approximately 20%
(range, 11–28%) of ingested strontium is absorbed from the
gastrointestinal tract. Balance measurements can be expected to yield
underestimates of absorption as a result of excretion of absorbed
strontium in the feces; nevertheless, the two methods have yielded
similar estimates of absorption.”
Regarding oral absorption, discussed in ATSDR (April 2004) and taking all available human data together approximately 20% of ingested strontium is absorbed from the gastrointestinal tract. In adult male rats, absorption of strontium as SrCl2is in a similar range (19%). Absorption in rats was found to be age dependent with higher absorption rates in very young animals and lower absorption rates in aged rats. However, it appears appropriate to use a default absorption factor for rats of 20% for risk assessment purposes.
Dermal absorption
In the absence of measured data on dermal absorption, current guidance suggests the assignment of either 10% or 100% default dermal absorption rates. In contrast, the currently available scientific evidence on dermal absorption of metals (predominantly based on the experience from previous EU risk assessments) yields substantially lower figures, which can be summarised briefly as follows:
Measured dermal absorption values for metals or metal compounds in studies corresponding to the most recent OECD test guidelines are typically 1 % or even less. Therefore, the use of a 10 % default absorption factor is not scientifically supported for metals. This is corroborated by conclusions from previous EU risk assessments (Ni, Cd, Zn), which have derived dermal absorption rates of 2 % or far less (but with considerable methodical deviations from existing OECD methods) from liquid media.
However, considering that under industrial circumstances many applications involve handling of dry powders, substances and materials, and since dissolution is a key prerequisite for any percutaneous absorption, a factor 10 lower default absorption factor may be assigned to such “dry” scenarios where handling of the product does not entail use of aqueous or other liquid media. This approach was taken in the in the EU RA on zinc. A reasoning for this is described in detail elsewhere (Cherrie and Robertson, 1995), based on the argument that dermal uptake is dependent on the concentration of the material on the skin surface rather than it’s mass.
The following default dermal absorption factors for metal cations are therefore proposed (reflective of full-shift exposure, i.e. 8 hours):
From exposure to liquid/wet media: 1.0
From dry (dust) exposure: 0.1 %
This approach is consistent with the methodology proposed in HERAG guidance for metals
(HERAG fact sheet - assessment of occupational dermal exposure and dermal absorption for metals and inorganic metal compounds; EBRC Consulting GmbH / Hannover /Germany; August 2007)
Inhalation absorption (for calculation please refer to the attached document)
The fate and uptake of deposited particles depends on the clearance mechanisms present in the different parts of the airway. In the head region, most material will be cleared rapidly, either by expulsion or by translocation to the gastrointestinal tract. A small fraction will be subjected to more prolonged retention, which can result in direct local absorption. More or less the same is true for the tracheobronchial region, where the largest part of the deposited material will be cleared to the pharynx (mainly by mucociliary clearance) followed by clearance to the gastrointestinal tract, and only a small fraction will be retained (ICRP, 1994). Once translocated to the gastrointestinal tract, the uptake will be in accordance with oral uptake kinetics.
According to ATSDR (2004) a ratio of 20% can be assumed for thegastrointestinal uptake and the material that is deposited in the pulmonary region may be assumed by default to be absorbed to 100%. This absorption value is chosen in the absence of relevant scientific data regarding alveolar absorption although knowing that this is a conservative choice. Thus, the following predicted inhalation absorption factors can be derived for strontium hydroxide:
|
absorption factor* |
Sample |
|
Strontium hydroxide octahydrate |
8.9 |
*: rounded values
Distribution
Following ingestion, the distribution of absorbed strontium in the human body is similar to that of calcium, with approximately 99% of the total body burden in the skeleton (ICRP 1993). The skeletal burden of stable strontium has been estimated from analyses of bone samples from human autopsies. Skeletal burden was estimated in Japanese adult males to be approximately 440 mg compared to 850 g of calcium.
One study was published in 1984 in which90Sr and calcium concentrations in human bone tissues and diets of people in the United Kingdom during the period from 1955 to 1970 were analyzed. The authors concluded that approximately 4.75% of the dietary intake of90Sr was taken up by the adult skeleton. Approximately 7.5% of the cortical bone90Sr burden was eliminated from bone each year (equivalent to elimination halftimes of approximately 9.2 years). The rate of elimination from trabecular bone was approximately 4 times this value. The same analysis yielded estimates of skeletal uptakes of strontium that varied with age, being highest, approximately 10%, in infants and during adolescence, ages in which bone growth rates are high relative to other ages.
The partitioning of strontium in blood has not been extensively explored. The concentrations of strontium in the erythrocyte and plasma fractions of human blood obtained from blood banks were 7.2 μg/L in the erythrocyte fraction and 44 μg/L in the plasma fraction, suggesting that most of the strontium in blood resides in the plasma (ATSDR, 2004).
Elimination
Strontium that has been absorbed from the gastrointestinal tract is excreted primarily in urine and feces. In two dial painters, rates of urinary and fecal excretion of radium approximately 10 years after the exposure were approximately 0.03 and 0.01% of the body burden per 24 hours, respectively. The urine: fecal excretion ratio of 3 that was observed in the radium dial workers is consistent with ratios of 2–6 observed several days to weeks after subjects received an intravenous injection of a soluble strontium comound. Thus, urine appears to be the major route of excretion of absorbed strontium. The observation of fecal excretion of radioactive strontium weeks to decades after an oral exposure or over shorter time periods after an intravenous exposure suggests the existence of a mechanism for transfer of absorbed strontium into gastrointestinal tract, either from the bile or directly from the plasma (ATSDR, 2004).
Metabolism
The metabolism of strontium consists of binding interactions with proteins and, based on its similarity to calcium, probably complex formation with various inorganic anions such as carbonate and phosphate, and carboxylic acids such as citrate and lactate. These types of interactions would be expected for all routes of exposure (ATSDR, 2004).
Data source
Materials and methods
Results and discussion
Applicant's summary and conclusion
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
